Prevail Innovative Wealth Advisors LLC Invests $4.38 Million in Zoetis Inc. $ZTS

Key Points

• Prevail Innovative Wealth Advisors opened a new Q3 position in Zoetis, acquiring 29,923 shares valued at about $4.38 million, while institutional investors now own roughly 92.8% of the stock.
• Zoetis beat quarterly expectations with $1.48 EPS (vs. $1.40 expected) and $2.39B revenue (vs. $2.36B), issued FY2026 guidance of $7.00–$7.10 EPS, and pays a quarterly dividend of $0.53 (annualized $2.12, ~1.7% yield).
• Analyst coverage is mixed: the consensus rating is a Hold with a consensus price target of $152.91 (six Buy, seven Hold, one Sell).

Prevail Innovative Wealth Advisors LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 29,923 shares of the company's stock, valued at approximately $4,378,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC lifted its holdings in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock valued at $25,000 after purchasing an additional 144 shares during the last quarter. Financial Consulate Inc. acquired a new position in Zoetis in the third quarter valued at $39,000. SJS Investment Consulting Inc. raised its holdings in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company's stock valued at $40,000 after buying an additional 257 shares during the last quarter. TruNorth Capital Management LLC purchased a new stake in shares of Zoetis in the third quarter valued at about $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Zoetis during the third quarter worth about $46,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on ZTS. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday, December 18th. Weiss Ratings downgraded Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, January 28th. Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. HSBC set a $140.00 target price on Zoetis in a research note on Wednesday, December 10th. Finally, Stifel Nicolaus dropped their target price on Zoetis from $140.00 to $130.00 and set a "hold" rating on the stock in a research report on Tuesday, November 18th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zoetis has a consensus rating of "Hold" and a consensus price target of $152.91.

Zoetis Trading Down 0.6%

Shares of ZTS opened at $121.54 on Friday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The stock has a market cap of $51.31 billion, a price-to-earnings ratio of 20.19, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The firm has a 50 day simple moving average of $126.06 and a 200-day simple moving average of $133.05.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis's dividend payout ratio (DPR) is presently 35.22%.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.